Cipla (CIPLA) Q4 22/23 earnings summary

Executive summary

• FY23 delivered record consolidated revenue of ₹22,753 crore, up 5% YoY and 11% excluding COVID; EBITDA was a record ₹5,027 crore at a 22.1% margin.

• One India and North America were key growth drivers; portfolio investment continued across complex generics, peptides, respiratory, wellness, biosimilars and digital health.

Financial highlights

• Consolidated revenue was ₹22,753 crore versus ₹21,763 crore in FY22; reported YoY growth was 5%, or 11% excluding COVID.

• EBITDA rose to ₹5,027 crore from ₹4,578 crore; margin expanded 106 bps YoY to 22.1%, supported by mix, cost discipline and operating efficiency.

• PAT was ₹2,802 crore, up 11.3% YoY; PAT margin was 12.3% versus 11.6%.

• Operating cash flow was ₹3,238 crore and free cash flow ₹2,104 crore; R&D spend increased ~20% to ₹1,344 crore.

Outlook and guidance

• FY24 One India priorities: sustain market-beating growth and core therapy volumes, raise chronic mix, improve medical representative productivity and enhance patient experience through digital analytics.

• North America FY24 focus: expand peptides, strengthen the complex-generic pipeline, grow respiratory and de-risk the US portfolio; revenue run rate expected to continue at the FY23 exit level.

• Consumer health EBITDA margin expected to reach the mid-teens in the upcoming year; international markets target double-digit growth in FY24.

• API outlook targets growth through organic launches, new pipeline molecules and wider reach into untapped markets.